Can-Fite BioPharma Ltd.

Tel Aviv Stock Exchange CANF.TA

Can-Fite BioPharma Ltd. Return on Assets (ROA) for the year ending December 31, 2023

Can-Fite BioPharma Ltd. Return on Assets (ROA) is NA for the year ending December 31, 2023. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Can-Fite BioPharma Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was -113.47%, a -82.45% change year over year.
Can-Fite BioPharma Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was -62.19%, a 60.00% change year over year.
Can-Fite BioPharma Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was -155.48%, a 2.63% change year over year.
Can-Fite BioPharma Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was -159.68%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Tel Aviv Stock Exchange: CANF.TA

Can-Fite BioPharma Ltd.

CEO	Mr. Motti Farbstein
IPO Date	Oct. 6, 2005
Location	Israel
Headquarters	10 Bareket Street
Employees	8
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Plastics

Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Key trends

Past 5 years